Mesothelioma | Mesothelioma

... Genomics and Proteomics - PerkinElmer and GMU Collaborate to Identify Biomarker for Cancer Detection News Headlines Interviews Market Reports Company Focus This Weeks News This Months News Submit a Press Release PerkinElmer and GMU Collaborate to Identify Biomarker for Cancer Detection Date Posted: Thursday, March 30, 2006 Options: Print PerkinElmer, Inc.

has announced a five-year research collaboration agreement with George Mason University to develop an approach for cancer detection and risk stratification.

Scientists from both organizations will work together on the design of several new types of clinical assay platforms that utilize both the amino acid identification of a protein fragment and its specific mass to identify the biomarker.

Areas of focused research include Stage I lung, ovarian and breast cancers.

"For improved patient outcomes, new diagnostics are needed," said Robert F.

Friel, president, PerkinElmer Life and Analytical Sciences.

"We are excited to provide technology that enables proteomic researchers to identify new biomarkers that may be able to detect cancer earlier." "Collaborating with George Mason University's Center for Applied Proteomics and Molecular Medicine provides an excellent opportunity to combine the superior technology of PerkinElmer and the systems biology research approach of this great institution." The alliance initially calls for the creation of a proteomics technology to accurately measure and detect specific protei...

... Life begins to go downhill at 30 - World - smh.com.au NEWS register www.smh.com.au Home » World » Article Life begins to go downhill at 30 Email Print Normal font Large font March 31, 2006 There was a time when biologists believed ageing was controlled by some inner mechanism that imposes an upper limit on life span.

But this explanation has fallen out of favour, replaced by the idea that it is simply a build-up of tiny faults and waste products as our cells go about their business.

In addition, the body starts to streamline itself after 30.

Between the ages of 30 and 80, a person will lose 40 per cent of muscle mass, for example.

Not only do we lose muscle fibres, but those left are weaker.

The story is similar with bones: the strength and mass of the skeleton rises until the early 30s, after which men lose about 1 per cent of their bone mass a decade.

Women lose bone at the same rate in the decade before menopause, but, on reaching menopause, the loss jumps to about 1 per cent a year for several years before going back to the same rate as men.

"In five years, women's skeletons age by 50 years compared with men," says Tim Skerry, a professor of ...

... PharmaLive: AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., as Chief Medical Officer TODAY ON PHARMALIVE.COM AVEO Pharmaceuticals Appoints John Ryan, Ph.D., M.D., as Chief Medical Officer Dr.

Ryan's Expertise in Translational Medicine a Key Addition as AVEO Moves its Portfolio of Novel Cancer Medicines Forward into the Clinic CAMBRIDGE, Mass., March 30, 2006 /PRNewswire/ - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer medicines, announced today that John L.

Ryan, Ph.D., M.D., has joined the company as Chief Medical Officer.

Dr.

Ryan will be responsible for clinical strategy and development of AVEO's pipeline, including AV-412, a novel dual kinase inhibitor scheduled to enter the clinic by the middle of this year.

Dr.

Ryan brings almost 20 years of experience in drug discovery and development to AVEO, including expertise in translational medicine and cancer biology.

He joins the company after 11 years at Wyeth where he most recently held the position of Senior Vice President of Translational Research.

In 2001, he was appointed head of the new Department of Experimental Medicine, which was created to explore new technologies such as pharmacogenomics in exploratory clinical trials, to work closely with FDA on clinical pharmacogenomics, and to bridge discovery and development with the creation of new biomarkers.

In 1998, he was promoted to Senior Vice President of Clinical Research & Development and assu...